However, in combination with docetaxel, ‘A3’ significantly decreased tumor size compared to docetaxel alone, demonstrating that pharmacologic targeting of the CHFR/PARP interaction may indeed be a promising strategy to improve taxane sensitivity in lung cancer. This evidence concerns the gene CHFR and lung cancer.